DOJ Restarts Cannabis Rescheduling Hearings After December Halt
Acting Attorney General resets marijuana Schedule III hearing process, replacing terminated December proceedings with new April framework.
The Department of Justice has reset the administrative hearing process for cannabis rescheduling, with Acting Attorney General Blanche issuing a fresh notice on April 28, 2026, to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The new hearing framework replaces proceedings that began in December 2024 but were abruptly terminated when the new notice was issued.
The restart signals continued federal momentum toward rescheduling, though the procedural reset introduces fresh uncertainty about timing. Cannabis operators have been pricing in Schedule III benefits including potential tax relief under Section 280E, which currently prevents marijuana businesses from deducting standard business expenses. The hearing restart keeps these tax advantages in play while extending the timeline for implementation.
The December hearing termination suggests the DOJ encountered procedural or substantive issues requiring a complete reset rather than continuation. This approach indicates the administration prioritizes getting the rescheduling process right over speed, potentially strengthening the final rule against legal challenges. However, the extended timeline creates additional regulatory overhang for cannabis companies operating under current Schedule I restrictions.
Multi-state operators stand to benefit most from eventual rescheduling through normalized tax treatment and reduced banking restrictions. Companies with significant federal tax burdens under 280E could see immediate margin expansion once Schedule III takes effect. The hearing process remains a critical checkpoint where opposition groups can challenge the scientific and legal basis for rescheduling.
The procedural restart demonstrates the complex administrative requirements for changing decades-old drug scheduling. While the direction toward Schedule III appears unchanged, the timeline extension affects investor expectations and capital allocation decisions across the cannabis sector. Companies continue operating under existing restrictions while awaiting the outcome of this reset hearing process.